Table 3. . Prognostic role of baseline characteristics and prostate-specific antigen response: univariate and multivariate analysis for progression-free survival.
| Univariate | Median OS (months) | HR (95% CI) | p-value |
|---|---|---|---|
| PSA response >50% | |||
| – Yes | 29.3 | 0.29 (0.18–0.48) | <0.001 |
| – No | 9.7 | ref. | |
| Gleason score | |||
| – <8 | 14.1 | 0.87 (0.52–1.46) | 0.603 |
| – ≥8 | 11.1 | ref. | |
| Primary treated | |||
| – Yes | 19.6 | 0.54 (0.34–0.87) | 0.011 |
| – No | 10.4 | ref. | |
| Previous docetaxel | |||
| – No | 21.5 | 0.49 (0.31–0.77) | 0.002 |
| – Yes | 10.5 | ref. | |
| Visceral metastasis | |||
| – No | 18.1 | 0.55 (0.31–0.95) | 0.033 |
| – Yes | 8.1 | ref. | |
| ECOG | |||
| – 0–1 | 18.1 | 0.21 (0.10–0.43) | <0.001 |
| – ≥2 | 3 | ref. | |
| ALP | |||
| – <ULN | 18.2 | 0.52 (0.32–0.84) | 0.008 |
| – ≥ULN | 10.5 | ref. | |
| Hemoglobin | |||
| – ≥12 g/dl | 18.4 | 0.54 (0.34–0.87) | 0.01 |
| – <12 g/dl | 10.5 | ref. | |
| Total PSA | |||
| – <Median | 25.8 | 0.30 (0.18–0.48) | <0.001 |
| – ≥Median | 9.5 | ref. | |
| LDH | |||
| – <Median | 18.4 | 0.68 (0.42–1.08) | 0.1 |
| – ≥Median | 14.6 | ref. | |
| Multivariate | |||
| PSA response >50% | |||
| – Yes | 0.19 (0.10–0.38) | <0.001 | |
| – No | ref. | ||
| Primary treated | |||
| – Yes | 0.47 (0.27–0.80) | 0.006 | |
| – No | ref. | ||
| Previous docetaxel | |||
| – 0 | 0.69 (0.41–1.14) | 0.148 | |
| – 1 | ref. | ||
| Visceral metastasis | |||
| – No | 0.64 (0.36–1.15) | 0.137 | |
| – Yes | ref. | ||
| ECOG | |||
| – 0–1 | 0.50 (0.21–1.18) | 0.112 | |
| – ≥2 | ref. | ||
| ALP | |||
| – <ULN | 0.73 (0.40–1.31) | 0.291 | |
| – ≥ULN | ref. | ||
| Hemoglobin | |||
| – ≥12 g/dl | 0.62 (0.34–1.14) | 0.121 | |
| – <12 g/dl | ref. | ||
| Total PSA | |||
| – <Median | 0.35 (0.20–0.59) | <0.001 | |
| – ≥Median | ref. |
ECOG: Eastern Cooperative Oncology Group; HR: Hazard ratio; IQR: Interquartile range; OS: Overall survival; PFS: Progression-free survival; PSA: Prostate-specific antigen; ULN: Upper limit of normal.